RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Semaglutide, tirzepatide and retatrutide have overlapping but different receptor targets and clinical research programs. The most useful comparison distinguishes a direct trial of two compounds from separate placebo-controlled trials. This review explains that distinction using published obesity studies. It does not rank research-use-only products for personal use or assume that a larger percentage in one study proves superiority over a compound tested elsewhere. [1–3]
WHAT DIFFERS ABOUT THE RECEPTOR TARGETS?
Semaglutide activates GLP-1 receptors. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity to GIP and GLP-1 activity. These descriptions identify the biological targets under investigation; they are not a scorecard in which more targets automatically means a better outcome. [2,3]
A clinical result depends on the complete molecule, the study intervention, the participants and the endpoint. Receptor activity is one part of that explanation. It cannot substitute for evidence about effectiveness, tolerability or longer-term outcomes in a defined population.
THE DIRECT TIRZEPATIDE–SEMAGLUTIDE COMPARISON
Aronne and colleagues reported SURMOUNT-5 in 2025. The randomized, open-label trial enrolled 751 adults with obesity without type 2 diabetes. At 72 weeks, estimated mean body-weight changes were minus 20.2% with tirzepatide and minus 13.7% with semaglutide under the study's treatment strategies. [2]
This directly supports a difference between the two groups for that endpoint in that trial. Open-label means participants and investigators knew the assigned treatment, which is a relevant design limitation. The result does not establish superiority for every disease, every formulation or every person.
It also does not prove which receptor caused the difference. Both complete molecules were compared; the trial did not experimentally isolate GIP activity while holding every other molecular property constant. Mechanistic interpretation should remain separate from the measured clinical comparison.
WHY THE SEMAGLUTIDE PERCENTAGE CAN VARY
In the earlier STEP 1 trial, Wilding and colleagues randomized 1,961 adults without diabetes to semaglutide or placebo with lifestyle intervention. Mean weight reductions at 68 weeks were 14.9% and 2.4%, respectively. [1]
That result and the semaglutide result in SURMOUNT-5 come from different experiments. Differences in recruitment, follow-up, treatment implementation and statistical methods can change an estimated average. Choosing whichever number is most favorable for an argument is less informative than reporting each result with its own study context.
WHAT RETATRUTIDE ADDS TO THE EVIDENCE
The 2026 TRIUMPH-1 publication reported a placebo-controlled retatrutide trial lasting 80 weeks. Its highest studied group had a mean weight reduction of 25.0%, versus 3.9% with placebo, using the reported treatment-regimen analysis. [3]
TRIUMPH-1 did not randomize participants to semaglutide or tirzepatide. Its percentages therefore cannot be placed beside SURMOUNT-5 as though all three compounds had been compared in one experiment. A numerical ordering across papers is not the same as a statistically tested treatment difference.
WHAT A FAIR COMPARISON NEEDS
First, the outcome must match. Change in body weight is different from change in blood glucose, liver tissue, cardiovascular events or kidney function. A compound can have strong evidence for one question while another question remains unresolved.
Second, the population and timeframe must match closely enough to support interpretation. Diabetes status, baseline disease, background treatment and follow-up duration can matter. A shorter study and a longer study do not provide interchangeable estimates simply because both report percentages.
Third, the analysis must be understood. Studies can estimate outcomes under different assumptions about treatment discontinuation and missing data. The phrase average weight change is therefore incomplete without knowing how the estimate was produced. Adverse effects and withdrawals also belong in any complete assessment; efficacy alone is not a safety comparison.
THE RESEARCH-USE BOUNDARY
These papers studied defined clinical products under formal protocols. They do not establish the identity, quality or suitability of an independently supplied laboratory batch. A shared compound name does not make two preparations interchangeable.
The evidence supports careful comparison of published research, with the strongest direct inference coming from participants randomized within the same trial. It does not support selecting or combining research chemicals for personal experimentation. Laboratory materials remain intended exclusively for qualified research and education.
REFERENCES
1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.
https://doi.org/10.1056/NEJMoa2032183
2. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393:26–36.
https://doi.org/10.1056/NEJMoa2416394
3. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Published online September 29, 2026.
https://doi.org/10.1056/NEJMoa2604169